- BetterLife Pharma (BETR) will be participating in the upcoming H.C. Wainwright’s Psychiatry and Beyond Virtual Conference on June 17
- CEO Dr. Ahmad Doroudian will detail the company’s product development pipeline
- BetterLife has retained Proactive Investors and Psychedelic Finance to broaden its reach within a global investor network
- BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals
- BetterLife Pharma Inc. (BETR) is down 1.47 per cent and is trading at C$0.34 at 12:50 pm ET
BetterLife Pharma (BETR) will be participating in the upcoming H.C. Wainwright’s Psychiatry and Beyond Virtual Conference on June 17.
Chief Executive Officer Dr. Ahmad Doroudian will detail the company’s product pipeline.
- H.C. Wainwright – Psychedelics in Psychiatry and Beyond Virtual Conference Registration & Webcast: https://hcwevents.com/psychedelics/
BetterLife has retained Proactive Investors and Psychedelic Finance to broaden its reach within a global investor network, as well as to assist with general market awareness.
Proactive will provide editorial coverage of BetterLife’s news releases, generate feature articles based on interviews with company executives, and produce video interviews.
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies.
BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.
BetterLife Pharma Inc. (BETR) is down 1.47 per cent and is trading at C$0.34 at 12:50 pm ET.
